6
A small dose I HOLLAND
LAUNCHES ONLINE TRAINING FOR PHARMA PROFESSIONALS
MOLECULAR DIAGNOSTICS FIRM
A
molecular diagnostics company has secured €25 million in funding to help address the spread of infectious diseases and antimicrobial resistance (AMR). The company, Mobidiag, secured the funding from the European Investment Bank (EIB) through the European Growth Finance Facility (EGFF) initiative.
T
abletting company I Holland has launched an online training programme to help pharma professionals keep up to date with the latest industry technology. The company’s e-learning programme offers professionals comprehensive and flexible courses across a range of disciplines. I Holland launched the programme in response to the growing demand from pharma professionals to learn about how technology is being used within the industry. Training managers and supervisors will be able to track and report on how each employee is developing, with the programme issuing a certification once each course is complete. The programme includes a variety of
subjects which will offer pharma professionals everything from introductions to tooling, maintaining tooling equipment, and how to improve productivity. Alex Bunting, I Holland marketing manager said: “We believe in supporting those in manufacturing who are looking to improve their technical skills and understanding of tablet compression tooling. However, we recognise that in the busy modern manufacturing environment, people can’t always be available to attend training and seminars. With that in mind we have created I Holland’s Online Training courses. They are designed for everyone from director level to engineers and operators looking to improve their knowledge in areas of tablet compression tooling.”
Mobidiag will use the funding - which is being supplied as a fouryear loan - to advance
Cell therapy company relocates to Cambridge A
UK cell therapy company has relocated to Cambridge Science Park following the appointment of 15 new staff. Mogrify has moved to the Bio-Innovation Centre at the Cambridge Science Park after it hired a range of new staff to help the company
advance its cell therapy goals. The company hopes that the new hires and facilities will aid it building a scalable infrastructure to generate IP around novel cell conversion to power the development and manufacture of new cell therapies across multiple therapeutic areas. The Bio-Innovation
Centre is the first of its kind to be built at the Cambridge Science Park and features laboratories and facilities for biotech and healthtech research. Mogrify has developed a bioinformatic platform that can potentially accelerate the conversion of one